Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429950 | 1.00 | EGFR (0.61) | EGFRERBB2MAPK14MAPK10 | |
| SCHEMBL26965257 | 0.81 | MAPK14 (0.57) | MAPK14MAPK10 | |
| SCHEMBL29429988 | 0.81 | MAPK14 (0.57) | MAPK14MAPK10 | |
| SCHEMBL29429962 | 0.80 | MAPK14 (0.57) | EGFRMAPK14MAPK10 | |
| SCHEMBL26965221 | 0.80 | MAPK14 (0.57) | EGFRMAPK14MAPK10 | |
| SCHEMBL29429883 | 0.80 | EGFR (0.63) | EGFRERBB2MAPK14MAPK10 | |
| SCHEMBL26965199 | 0.80 | EGFR (0.63) | EGFRERBB2MAPK14MAPK10 | |
| SCHEMBL22470980 | 0.80 | EGFR (0.62) | EGFRERBB2MAPK14MAPK10 | |
| SCHEMBL29429909 | 0.78 | MAPK14 (0.46) | MAPK14MAPK10 | |
| SCHEMBL26965125 | 0.73 | MAPK14 (0.56) | MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406838-A1 | MUTANT SELECTIVE EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885MAPK14 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.